nach oben

Current Rheumatology Reports

Erschienen in:

01.08.2014 | Pediatric Rheumatology (S Ozen, Section Editor)

Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis

verfasst von: Rosa Bou, Estíbaliz Iglesias, Jordi Antón

Erschienen in: Current Rheumatology Reports | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

Chronic anterior uveitis affects 10–30 % of patients with juvenile idiopathic arthritis (JIA) and is still a cause of blindness in childhood. In most patients it is asymptomatic, bilateral, and recurrent, so careful screening and early diagnosis are important to obtain the best long-term prognosis. The treatment of chronic uveitis associated with JIA is challenging. Initial treatment is based on topical steroids and mydriatic drops. Methotrexate is the most common first-line immunomodulatory drug used. For refractory patients, biologicals, mainly the anti-tumor-necrosis-factor (TNF) drugs adalimumab and infliximab, have been revealed to be effective and have changed the outcome for these patients. Collaboration between pediatric rheumatologists and ophthalmologists is important for the successful diagnosis and treatment of patients with uveitis associated with JIA.

Carvounis PE, Herman DC, Cha S, Burke JP. Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature. Graefes Arch Clin Exp Ophthalmol. 2006;244:281–90.PubMedCrossRef

Petty RE, Smith JR, Rosenbaum JT. Arthritis and uveitis in children: A pediatric rheumatology perspective. Am J Ophthalmol. 2003;135:879–84.PubMedCrossRef

Sabri K, Saurenmann RK, Silverman ED, Levin AV. Course, complications, and outcome of juvenile arthritis-related uveitis. J AAPOS. 2008;12:539–45.PubMedCrossRef

Heiligenhaus A et al. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford). 2007;46(1015–1019).

Cassidy J, Kivlin J, Lindsley C, Nocton J. Ophthalmologic examinations in children with juvenile rheumatoid arthritis. Pediatrics. 2006;117:1843–5.PubMedCrossRef

De Boer J, Wulffraat N, Rothova A. Visual loss in uveitis of childhood. Br J Ophthalmol. 2003;87:879–84.PubMedCentralPubMedCrossRef

Pelegrín L et al. Predictive Value of Selected Biomarkers, Polymorphisms, and Clinical Features for Oligoarticular Juvenile Idiopathic Arthritis-associated Uveitis. Ocul Immunol Inflamm. 2013. doi:10.3109/09273948.2013.841495.

Nordal EB et al. Biomarkers of chronic uveitis in juvenile idiopathic arthritis: predictive value of antihistone antibodies and antinuclear antibodies. J Rheumatol. 2009;36:1737–43.PubMedCrossRef

Angeles-Han ST, Yeh S, Vogler LB. Updates on the risk markers and outcomes of severe juvenile idiopathic arthritis-associated uveitis. Int J Clin Rheumtol. 2013(8).

10.

Kalinina Ayuso V et al. Intraocular biomarker identification in uveitis associated with juvenile idiopathic arthritis. Invest Ophthalmol Vis Sci. 2013;54:3709–20.PubMedCrossRef

11.••

Heiligenhaus A et al. Proposed outcome measures for prospective clinical trials in juvenile idiopathic arthritis-associated uveitis: a consensus effort from the multinational interdisciplinary working group for uveitis in childhood. Arthritis Care Res (Hoboken). 2012;64:1365–72. Proposed core set of outcome measures for clinical trials in JIA-uveitis that have reached consensus by an international multidisciplinary working group of experts in uveitis.CrossRef

12.

Thorne JE, Woreta FA, Dunn JP, Jabs DA. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology. 2010;117:1436–41.PubMedCentralPubMedCrossRef

13.

Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2005;32:362–5.PubMed

14.

Kalinina Ayuso V, van de Winkel EL, Rothova A, de Boer JH. Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis. Am J Ophthalmol. 2011;151:217–22.PubMedCrossRef

15.

Heiligenhaus A, Mingels A, Heinz C, Ganser G. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur J Ophthalmol. 2007;17:743–8.PubMed

16.•

Simonini G, Paudyal P, Jones GT, Cimaz R, Macfarlane GJ. Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach. Rheumatology (Oxford). 2013;52:825–31. Meta-analysys on efficacy and safety of methotrexate in childhood uveitis, including 135 patients from 9 different studies.CrossRef

17.

Goebel JC et al. Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis. Br J Ophthalmol. 2011;95:209–13.PubMedCrossRef

18.••

Heiligenhaus A et al. Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int. 2012;32:1121–33. German clinical gidelines for treatment of JIA-uveitis, including a therapeutic algorithm.PubMedCrossRef

19.

Teoh SC, Hogan AC, Dick AD, Lee RWJ. Mycophenolate mofetil for the treatment of uveitis. Am J Ophthalmol. 2008;146:752–60. 760.e1–3.PubMedCrossRef

20.

Daniel E et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010;149:423–32. e1–2.PubMedCentralPubMedCrossRef

21.

Sobrin L, Christen W, Foster CS. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology. 2008;115:1416–21. 1421.e1.PubMedCrossRef

22.

Doycheva D, Deuter C, Stuebiger N, Biester S, Zierhut M. Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol. 2007;91:180–4.PubMedCentralPubMedCrossRef

23.

Chang PY et al. Mycophenolate mofetil monotherapy in the management of paediatric uveitis. Eye (Lond). 2011;25(427–35).

24.

Silverman E et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med. 2005;352:1655–66.PubMedCrossRef

25.

Molina C, Modesto C, Martín-Begué N, Arnal C. Leflunomide, a valid and safe drug for the treatment of chronic anterior uveitis associated with juvenile idiopathic arthritis. Clin Rheumatol. 2013;32:1673–5.PubMedCrossRef

26.

Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology. 2006;113:860–4.e2.PubMedCrossRef

27.

Rajaraman RT, Kimura Y, Li S, Haines K, Chu DS. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology. 2006;113:308–14.PubMedCrossRef

28.

Richards JC, Tay-Kearney M-L, Murray K, Manners P. Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Exp Ophthalmol. 2005;33:461–8.CrossRef

29.

Tynjälä P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis. 2007;66:548–50.PubMedCentralPubMedCrossRef

30.•

Zannin ME et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol. 2013;40:74–9. Data from the National Italian Registryincludes 108 children with JIA-uveitis treated with infliximab or adalimumab.PubMedCrossRef

31.

Kruh JN, Yang P, Suelves AM, Foster CS. Infliximab for the treatment of refractory noninfectious Uveitis: a study of 88 patients with long-term follow-up. Ophthalmology. 2014;121:358–64.PubMedCrossRef

32.

Sukumaran S, Marzan K, Shaham B, Reiff A. High dose infliximab in the treatment of refractory uveitis: does dose matter? ISRN Rheumatol. 2012;2012(765380).

33.

Tambralli A et al. High doses of infliximab in the management of juvenile idiopathic arthritis. J Rheumatol. 2013;40:1749–55.PubMedCrossRef

34.

Simonini G et al. Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis. Rheumatology (Oxford). 2008;47(1510–4).

35.

Steenholdt C. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn’s disease. Dan Med J. 2013;60:B4616.PubMed

36.

Bravo-Ljubetic L, Peralta-Calvo J, Noval S, Pastora-Salvador N, Abelairas-Gómez J. Adalimumab therapy for refractory childhood uveitis. J AAPOS. 2013;17:456–9.PubMedCrossRef

37.

Kotaniemi K, Säilä H, Kautiainen H. Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin Ophthalmol. 2011;5:1425–9.PubMedCentralPubMedCrossRef

38.

Dobner BC et al. A three-centre experience with adalimumab for the treatment of non-infectious uveitis. Br J Ophthalmol. 2013;97:134–8.PubMedCrossRef

39.

Vazquez-Cobian LB, Flynn T, Lehman TJA. Adalimumab therapy for childhood uveitis. J Pediatr. 2006;149:572–5.PubMedCrossRef

40.

Biester S et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007;91:319–24.PubMedCentralPubMedCrossRef

41.

Tynjälä P et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford). 2008;47(339–44).

42.•

García-De-Vicuña C et al. Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis. Mediat Inflamm. 2013;2013:560632. Results from a multicentric study of 39 children with uveitis associated with JIA treated with adalimumab.

43.

Magli A et al. Adalimumab for juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol. 2013;251:1601–6.PubMedCrossRef

44.

Ramanan A. V et al. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial). Trials. 2014;15:14.PubMedCentralPubMedCrossRef

45.

Simonini G et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken). 2011;63(612–8).

46.

Doycheva D et al. Immunomodulatory therapy with tumour necrosis factor α inhibitors in children with antinuclear antibody-associated chronic anterior uveitis: long-term results. Br J Ophthalmol. 2014;98:523–8.PubMedCrossRef

47.

Lovell DJ et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359:810–20.PubMedCrossRef

48.

Smith JA et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 2005;53:18–23.PubMedCrossRef

49.

Saurenmann RK et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford). 2006;45(982–9).

50.

Leu JH et al. A36: Long-term Pharmacokinetics of Body Surface Area-Adjusted Doses of Golimumab Following Repeated Subcutaneous Administrations in Pediatric Patients With Polyarticular Juvenile Idiopathic Arthritis. Arthritis Rheumatol (Hoboken, NJ). 2014;66 Suppl 1:S55–6.CrossRef

51.

Brunner H et al. A148: a multi-center, double-blind, randomized-withdrawal trial of subcutaneous golimumab in pediatric patients with active polyarticular course juvenile idiopathic arthritis despite methotrexate therapy: week 48 results. Arthritis Rheumatol (Hoboken, NJ). 2014;66 Suppl 1:S191–2.CrossRef

52.

William M, Faez S, Papaliodis GN, Lobo A-M. Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. J Ophthal Inflamm Infect. 2012;2:231–3.CrossRef

53.

Cordero-Coma M, Salom D, Díaz-Llopis M, López-Prats MJ, Calleja S. Golimumab for uveitis. Ophthalmology. 2011;118:1892.e3–4.CrossRef

54.

Miserocchi E, Modorati G, Pontikaki I, Meroni P, Gerloni V. Golimumab treatment for complicated uveitis. Clin Exp Rheumatol. 2013;31:320–1.PubMed

55.

Miserocchi E, Modorati G, Pontikaki I, Meroni PL, Gerloni V. Long-term Treatment with Golimumab for Severe Uveitis. Ocul Immunol Inflamm. 2013;22:90–5.PubMedCrossRef

56.

Tappeiner C, Heinz C, Ganser G, Heiligenhaus A. Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol. 2012;39:1294–5.PubMedCrossRef

57.

Adán A, Mesquida M, Llorenç V, Modesto C. Tocilizumab for retinal vasoproliferative tumor secondary to juvenile idiopathic arthritis-associated uveitis: a case report. Graefes Arch Clin Exp Ophthalmol. 2013. doi:10.1007/s00417-013-2466-5.

58.

An Open-label Trial to Assess the Efficacy and Safety of Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Vision-threatening Uveitis That is Refractory to Other Modes of Systemic Immunosuppression. at http://www.clinicaltrials.gov/ct2/show/NCT01603355.

59.

Angeles-han S, Flynn T, Lehman T. Abatacept for Refractory Juvenile Idiopathic Arthritis-Associated Uveitis −− A Case Report. J Rheumatol. 2008(35).

60.

Elhai M, Deslandre CJ, Kahan A. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Comment on the article by Zulian et al. Arthritis Care Res (Hoboken). 2011;63:307–8. author reply 308.CrossRef

61.

Kenawy N et al. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol. 2011;249:297–300.PubMedCrossRef

62.

Zulian F et al. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken). 2010;62(821–5).

63.

An Openlabel, Phase II Trial of Abatacept (Orencia) in the Treatment of Refractory Non-infectious Uveitis. at http://www.clinicaltrials.gov/ct2/show/NCT01279954.

64.

Heiligenhaus A, Miserocchi E, Heinz C, Gerloni V, Kotaniemi K. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford). 2011;50(1390–1394).

65.

Miserocchi E et al. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev. 2011;11:35–9.PubMedCrossRef

Titel: Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis
verfasst von: Rosa Bou
Estíbaliz Iglesias
Jordi Antón
Publikationsdatum: 01.08.2014
Verlag: Springer US
Erschienen in: Current Rheumatology Reports / Ausgabe 8/2014
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-014-0437-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Typ-1-Diabetes | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2014

Is Statin-Induced Myositis Part of the Polymyositis Disease Spectrum?

Treatment of Severe and/or Refractory ANCA-Associated Vasculitis

Vaccinations for Rheumatoid Arthritis

Vaccination in Paediatric Rheumatology

Use of DXA-Based Technology for Detection and Assessment of Risk of Vertebral Fracture in Rheumatology Practice

Ayurvedic Medicine for Rheumatoid Arthritis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Update Innere Medizin